Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delavirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | MAOA | P21397 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | MDH1 | P40925 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.98 |
| ▸ | SYK | P43405 | 14/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delavirdine SCHEMBL40522 | 1.00 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29585604 | 1.00 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30703160 | 0.99 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29602259 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29714124 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30803764 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL34420 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL28170537 | 0.98 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29746247 | 0.98 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL6390522 | 0.91 | ADRA2A (0.82) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478324-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| EP-3452483-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-3328875-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-06-06 | — | — | EP | disclosed |
| EP-3317271-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018002902-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017191545-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017130156-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2013076586-A2 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENTS | ADVANCED BIOLOGICAL LABORATORIES SA (LU) | 2013-05-30 | — | — | WO | disclosed |
| US-20050214288-A1 | Antibodies against Nogo receptor | HUMAN GENOME SCIENCES, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1480772-A4 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES INC (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1592684-A | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | BURSTEIN TECHNOLOGIES INC (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1480772-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | Burstein Technologies, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030129665-A1 | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | VINDUR TECHNOLOGIES, INC. (NO) | 2003-07-10 | — | — | US | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003021223-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2001054717-A1 | VACCINE COMPOSITION, PROCESS AND METHODS | JIRA VIC (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | ADRA2A 1906/4885ADORA3 1923/4885CHRM1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.